Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

Stock Information for Co-Diagnostics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Co-Diagnostics Inc.

Life Sciences Investor Forum Agenda Announced for June 11th-12th
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25
Bio-Path Holdings Provides Clinical and Operational Update
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
Bio-Path Holdings Reports Full Year 2024 Financial Results
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Bio-Path Holdings Expands Global Patent Portfolio

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.